关注世界糖尿病日:世卫组织首次启动胰岛素预认证规划

2019-11-14 朱赫 央视新闻

11月14日是世界糖尿病日,根据世界卫生组织的数据,截至目前全球已有超过4.2亿糖尿病患者,其中约2000万是1型糖尿病患者,绝大部分为2型糖尿病患者。糖尿病是第七大死亡原因,也是导致心脏病发作、中风、肾衰竭、失明等并发症的主要原因。目前糖尿病患病率在全球范围内都在稳定增长,胰岛素仍然是重要的治疗方式。所有1型糖尿病患者和约6500万的2型糖尿病患者,都需要使用胰岛素治疗。但据世卫组织统计,650

11月14日是世界糖尿病日,根据世界卫生组织的数据,截至目前全球已有超过4.2亿糖尿病患者,其中约2000万是1型糖尿病患者,绝大部分为2型糖尿病患者。糖尿病是第七大死亡原因,也是导致心脏病发作、中风、肾衰竭、失明等并发症的主要原因。

目前糖尿病患病率在全球范围内都在稳定增长,胰岛素仍然是重要的治疗方式。所有1型糖尿病患者和约6500万的2型糖尿病患者,都需要使用胰岛素治疗。但据世卫组织统计,6500万需要胰岛素治疗的2型糖尿病患者中,约有一半人群无法获得胰岛素。许多需要胰岛素的糖尿病患者由于经济困难,冒生命危险不使用胰岛素。在某些国家,一个月的胰岛素供应花费占到一个工人收入的15%~22%。

由于全球胰岛素市场被部分药企控制,设定的价格过于高昂,世卫组织宣布启动试点规划,对人胰岛素进行预认证,鼓励更多药企通过世卫组织认证后批量生产胰岛素,有助于增加国际市场上有质量保证的胰岛素产品供应,为各国患者提供更多选择和更低价格的胰岛素,以加强对糖尿病的治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1967010, encodeId=0c1a196e0103c, content=<a href='/topic/show?id=cc43e67317a' target=_blank style='color:#2F92EE;'>#糖尿病日#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76731, encryptionId=cc43e67317a, topicName=糖尿病日)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Aug 25 08:03:00 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672521, encodeId=12c616e252115, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Thu Dec 12 03:03:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750111, encodeId=99041e50111ef, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jul 01 09:03:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820064, encodeId=284a182006449, content=<a href='/topic/show?id=dad61002e4a3' target=_blank style='color:#2F92EE;'>#预认证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100274, encryptionId=dad61002e4a3, topicName=预认证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jun 11 16:03:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300866, encodeId=f6ba130086637, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 16 02:03:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375263, encodeId=61073e52632b, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:05:50 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042818, encodeId=15a3104281888, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 14 14:03:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1967010, encodeId=0c1a196e0103c, content=<a href='/topic/show?id=cc43e67317a' target=_blank style='color:#2F92EE;'>#糖尿病日#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76731, encryptionId=cc43e67317a, topicName=糖尿病日)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Aug 25 08:03:00 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672521, encodeId=12c616e252115, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Thu Dec 12 03:03:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750111, encodeId=99041e50111ef, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jul 01 09:03:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820064, encodeId=284a182006449, content=<a href='/topic/show?id=dad61002e4a3' target=_blank style='color:#2F92EE;'>#预认证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100274, encryptionId=dad61002e4a3, topicName=预认证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jun 11 16:03:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300866, encodeId=f6ba130086637, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 16 02:03:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375263, encodeId=61073e52632b, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:05:50 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042818, encodeId=15a3104281888, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 14 14:03:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-12-12 respect
  3. [GetPortalCommentsPageByObjectIdResponse(id=1967010, encodeId=0c1a196e0103c, content=<a href='/topic/show?id=cc43e67317a' target=_blank style='color:#2F92EE;'>#糖尿病日#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76731, encryptionId=cc43e67317a, topicName=糖尿病日)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Aug 25 08:03:00 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672521, encodeId=12c616e252115, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Thu Dec 12 03:03:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750111, encodeId=99041e50111ef, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jul 01 09:03:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820064, encodeId=284a182006449, content=<a href='/topic/show?id=dad61002e4a3' target=_blank style='color:#2F92EE;'>#预认证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100274, encryptionId=dad61002e4a3, topicName=预认证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jun 11 16:03:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300866, encodeId=f6ba130086637, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 16 02:03:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375263, encodeId=61073e52632b, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:05:50 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042818, encodeId=15a3104281888, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 14 14:03:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2020-07-01 baoya
  4. [GetPortalCommentsPageByObjectIdResponse(id=1967010, encodeId=0c1a196e0103c, content=<a href='/topic/show?id=cc43e67317a' target=_blank style='color:#2F92EE;'>#糖尿病日#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76731, encryptionId=cc43e67317a, topicName=糖尿病日)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Aug 25 08:03:00 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672521, encodeId=12c616e252115, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Thu Dec 12 03:03:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750111, encodeId=99041e50111ef, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jul 01 09:03:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820064, encodeId=284a182006449, content=<a href='/topic/show?id=dad61002e4a3' target=_blank style='color:#2F92EE;'>#预认证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100274, encryptionId=dad61002e4a3, topicName=预认证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jun 11 16:03:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300866, encodeId=f6ba130086637, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 16 02:03:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375263, encodeId=61073e52632b, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:05:50 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042818, encodeId=15a3104281888, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 14 14:03:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1967010, encodeId=0c1a196e0103c, content=<a href='/topic/show?id=cc43e67317a' target=_blank style='color:#2F92EE;'>#糖尿病日#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76731, encryptionId=cc43e67317a, topicName=糖尿病日)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Aug 25 08:03:00 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672521, encodeId=12c616e252115, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Thu Dec 12 03:03:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750111, encodeId=99041e50111ef, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jul 01 09:03:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820064, encodeId=284a182006449, content=<a href='/topic/show?id=dad61002e4a3' target=_blank style='color:#2F92EE;'>#预认证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100274, encryptionId=dad61002e4a3, topicName=预认证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jun 11 16:03:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300866, encodeId=f6ba130086637, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 16 02:03:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375263, encodeId=61073e52632b, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:05:50 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042818, encodeId=15a3104281888, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 14 14:03:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1967010, encodeId=0c1a196e0103c, content=<a href='/topic/show?id=cc43e67317a' target=_blank style='color:#2F92EE;'>#糖尿病日#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76731, encryptionId=cc43e67317a, topicName=糖尿病日)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Aug 25 08:03:00 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672521, encodeId=12c616e252115, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Thu Dec 12 03:03:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750111, encodeId=99041e50111ef, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jul 01 09:03:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820064, encodeId=284a182006449, content=<a href='/topic/show?id=dad61002e4a3' target=_blank style='color:#2F92EE;'>#预认证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100274, encryptionId=dad61002e4a3, topicName=预认证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jun 11 16:03:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300866, encodeId=f6ba130086637, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 16 02:03:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375263, encodeId=61073e52632b, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:05:50 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042818, encodeId=15a3104281888, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 14 14:03:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-15 14794e5bm67(暂无昵称)

    学习了,不错的话题,非常精彩,受益非浅

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1967010, encodeId=0c1a196e0103c, content=<a href='/topic/show?id=cc43e67317a' target=_blank style='color:#2F92EE;'>#糖尿病日#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76731, encryptionId=cc43e67317a, topicName=糖尿病日)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Aug 25 08:03:00 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672521, encodeId=12c616e252115, content=<a href='/topic/show?id=60819060283' target=_blank style='color:#2F92EE;'>#规划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90602, encryptionId=60819060283, topicName=规划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676926912123, createdName=respect, createdTime=Thu Dec 12 03:03:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750111, encodeId=99041e50111ef, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed Jul 01 09:03:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820064, encodeId=284a182006449, content=<a href='/topic/show?id=dad61002e4a3' target=_blank style='color:#2F92EE;'>#预认证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100274, encryptionId=dad61002e4a3, topicName=预认证)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jun 11 16:03:00 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300866, encodeId=f6ba130086637, content=<a href='/topic/show?id=d6f720e61ab' target=_blank style='color:#2F92EE;'>#世卫组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20761, encryptionId=d6f720e61ab, topicName=世卫组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Nov 16 02:03:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375263, encodeId=61073e52632b, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:05:50 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042818, encodeId=15a3104281888, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 14 14:03:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-14 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

联合国糖尿病日|36地共同点亮蓝光,九大举措助女性防糖

11月14日晚,全国将有34地,36个地标建筑,在同一时间,共同点亮蓝光。这就是吸引全国32个省级行政区,预计100多个城市共同参与的2017年联合国糖尿病日暨蓝光行动(以下简称“蓝光行动”)。今年蓝光行动的主题仍延用联合国糖尿病日的主题:女性与糖尿病——我们拥有健康未来的权利。呼吁所有患糖尿病及面临糖尿病风险的女性,都有获得糖尿病防治知识权利,助力于预防和控制女性糖尿病。随着生活水平提高,人们也

糖化血红蛋白:血糖监测金标准

  糖尿病患者在家中开展毛细血管血糖监测被称为“自我血糖监测(SMBG)”,是目前最具实用价值的一种血糖监测方式,受到国内外糖尿病专业学会的支持和推荐。   糖化血红蛋白是糖尿病专业学会推荐的应定期监测的指标。我国糖尿病学会推荐,新诊断的糖尿病患者和血糖未达标的患者应每3个月到医院测量一次糖化血红蛋白,而血糖已基本达标的患者则可3~6个月测量一次糖化血红蛋白。通过标准方法测定的糖化血红蛋白的正常

2013糖尿病日暨蓝光行动:糖尿病教育与预防

我国的糖尿病患病人数正在快速增长。中华医学会糖尿病学分会的调查显示,我国成人中每10人就有1名糖尿病患者,而处于糖尿病前期的人数更是超过了糖尿病患者人数。 世界卫生组织、国际糖尿病联盟将每年的11月14日定为联合国糖尿病日,以唤起全社会对糖尿病防治的关注。中华医学会糖尿病学分会自2010年起,每年在糖尿病日期间举办“糖尿病防治蓝光行动”,开展公众糖尿病知晓教育并团结社会各界共同致力于糖尿

介入治疗在糖尿病足患者中的应用

  糖尿病足作为糖尿病的一种严重并发症,具有很高的致残率和致死率,部分糖尿病足坏疽患者都会经历溃疡、截肢、死亡的过程。   随着血管腔内技术逐渐发展成熟, 如内膜下血管成形术、切割球囊、小外径低顺应性高压力球囊、药物洗脱支架和可吸收支架的应用,在美国接受外周动脉腔内介入治疗的糖尿病下肢血管病变和糖尿病足的患者数已经超过行冠状动脉介入治疗的患者,大多数糖尿病足患者采用下肢血管腔内介入治疗